Trial Number



Pediatric Cancer, Brain Tumor

Participant Age Range

12 months to 21 years

Participant Gender


Enrolling Participants



A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)

This is a study to see if a new medication called selinexor can help improve the survival of children with aggressive brain tumors called DIPG, DMG and other types of pediatric brain tumors. There tumors are very difficult to treat and have low long-term survival rates. Selinexor works by blocking a protein that helps tumors grow. In this study, children will receive selinexor along with radiation therapy, followed by selinexor as a maintenance therapy. We want to see if this combination can help children live longer and prevent the tumor from coming back.


Related Clinical Trials

Click on the category you are interested in.

Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
This registration is for:
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.